Skip to main content
Top
Published in: Diabetologia 3/2005

01-03-2005 | Article

Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study

Authors: G. Bruno, F. Merletti, A. Biggeri, G. Bargero, S. Ferrero, G. Pagano, P. Cavallo-Perin

Published in: Diabetologia | Issue 3/2005

Login to get access

Abstract

Aims/hypothesis

Fibrinogen and elevated AER increase cardiovascular mortality, but few data are available in the type 2 diabetic population. We have conducted an 11-year follow-up study of the Casale Monferrato cohort to assess: (1) the long-term predictive role of AER independently of conventional risk factors; (2) the shape of its relationship with cardiovascular mortality; and (3) whether fibrinogen has a predictive effect independent of the increased cardiovascular risk associated with nephropathy.

Methods

During the follow-up period (1991–2001) a population-based cohort of 1,565 patients was regularly examined, and measurements of HbA1c were centralised. Multivariate Cox proportional hazards modelling was employed to assess the role of fibrinogen and AER as predictors of all-cause and cardiovascular mortality, independently of baseline variables and individual cumulative average values of HbA1c during follow-up.

Results

In 10,890.2 person-years of observations, 685 deaths were identified, giving an all-cause mortality rate of 63.4 per 1,000 person-years (95% CI 58.8–68.3). In Cox regression analyses, the strongest predictor of cardiovascular mortality was macroalbuminuria (relative risk 2.18, 95% CI 1.62–2.94), which was mainly associated with a high risk of short-term mortality. No increased risk was evident until the upper microalbuminuric range of AER values. Plasma fibrinogen was also a major independent predictor, and its role was not modified by AER, or by the exclusion of subjects developing chronic renal failure or diabetic nephropathy during follow-up.

Conclusions/interpretation

The results indicate that: (1) AER is the main independent predictor of 11-year cardiovascular mortality; (2) this effect is mainly evident in the upper range of microalbuminuria and in macroalbuminuria; and (3) fibrinogen has an independent effect on cardiovascular mortality, but no synergistic effect with AER, suggesting that both endothelial dysfunction and chronic inflammation are involved in the excess cardiovascular mortality of type 2 diabetic patients.
Literature
1.
go back to reference Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P (1999) The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 19:1776–1783 Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P (1999) The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 19:1776–1783
2.
go back to reference Yano K, Grove JS, Chen R, Rodriguez BL, Curb JD, Tracy RP (2001) Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese–American men. Arterioscler Thromb Vasc Biol 21:1065–1070 Yano K, Grove JS, Chen R, Rodriguez BL, Curb JD, Tracy RP (2001) Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese–American men. Arterioscler Thromb Vasc Biol 21:1065–1070
3.
go back to reference Yarnell JWG, Patterson CC, Sweetnam PM, Lowe GDO (2004) Haemostatic/inflammatory markers predict 10-yr risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J 25:1049–1056 Yarnell JWG, Patterson CC, Sweetnam PM, Lowe GDO (2004) Haemostatic/inflammatory markers predict 10-yr risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J 25:1049–1056
4.
go back to reference Engström G, Hedblad B, Stavenow L et al (2004) Fatality of future coronary events is related to inflammation-sensitive plasma proteins. A population-based prospective cohort study. Circulation 110:27–31CrossRef Engström G, Hedblad B, Stavenow L et al (2004) Fatality of future coronary events is related to inflammation-sensitive plasma proteins. A population-based prospective cohort study. Circulation 110:27–31CrossRef
5.
go back to reference Engström G, Stavenow L, Hedblad B et al (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke. A population-based study. Diabetes 52:442–447 Engström G, Stavenow L, Hedblad B et al (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke. A population-based study. Diabetes 52:442–447
6.
go back to reference Stehouwer CD, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMed Stehouwer CD, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMed
7.
go back to reference Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ (2003). Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabet Med 20:147–151 Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ (2003). Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabet Med 20:147–151
8.
go back to reference Greaves M, Malia RG, Goodfellow K et al (1997) Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Diabetologia 40:698–705 Greaves M, Malia RG, Goodfellow K et al (1997) Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Diabetologia 40:698–705
9.
go back to reference Klein RL, Hunter SJ, Jenkins AJ et al (2003) Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 26:1439–1448 Klein RL, Hunter SJ, Jenkins AJ et al (2003) Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 26:1439–1448
10.
go back to reference Bruno G, Cavallo-Perin P, Bargero G, Borra M, D’Errico N, Pagano G (1996) The associations of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes. Ann Intern Med 125:653–657PubMed Bruno G, Cavallo-Perin P, Bargero G, Borra M, D’Errico N, Pagano G (1996) The associations of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes. Ann Intern Med 125:653–657PubMed
11.
go back to reference Bruno G, Merletti F, Biggeri A et al (2003) Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26:2150–2155 Bruno G, Merletti F, Biggeri A et al (2003) Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26:2150–2155
12.
go back to reference Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418CrossRefPubMed Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418CrossRefPubMed
13.
go back to reference Forsblom CM, Sane T, Groop P-H et al (1998) Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence for a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41:1253–1262CrossRefPubMed Forsblom CM, Sane T, Groop P-H et al (1998) Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence for a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41:1253–1262CrossRefPubMed
14.
go back to reference Gerstein HC, Mann JFE, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRefPubMed Gerstein HC, Mann JFE, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRefPubMed
15.
go back to reference Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100 Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093–1100
16.
go back to reference Yuyun MF, Dinnen SF, Edwards OM, Wood E, Warehan NJ (2003) Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20:277–282 Yuyun MF, Dinnen SF, Edwards OM, Wood E, Warehan NJ (2003) Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20:277–282
17.
go back to reference Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS (1995) Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013–1016PubMed Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS (1995) Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013–1016PubMed
18.
go back to reference Agewall S, Wikstrand J, Ljungman S, Fagerberg B, Risk Factor Intervention Study Group (1997) Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 80:164–169 Agewall S, Wikstrand J, Ljungman S, Fagerberg B, Risk Factor Intervention Study Group (1997) Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 80:164–169
19.
go back to reference Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H (1995) Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303–1309 Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H (1995) Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303–1309
20.
go back to reference MacLeod JM, Lutale J, Marshall SM (1995) Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610–616 MacLeod JM, Lutale J, Marshall SM (1995) Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610–616
21.
go back to reference Östgren CJ, Lindblad U, Melander A, Råstam L (2002) Survival in patients with type 2 diabetes in a Swedish community: Skaraborg Hypertension and Diabetes Project. Diabetes Care 25:1297–1302 Östgren CJ, Lindblad U, Melander A, Råstam L (2002) Survival in patients with type 2 diabetes in a Swedish community: Skaraborg Hypertension and Diabetes Project. Diabetes Care 25:1297–1302
22.
go back to reference Hillege HL, Fidler V, Diercks GFH et al (2002) Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation 106:1777–1782CrossRefPubMed Hillege HL, Fidler V, Diercks GFH et al (2002) Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation 106:1777–1782CrossRefPubMed
23.
go back to reference Fuller JH, Stevens LK, Wang S-L, WHO Multinational Study Group (2001) Risk factors for cardiovascular mortality and morbidity: the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S54–S64 Fuller JH, Stevens LK, Wang S-L, WHO Multinational Study Group (2001) Risk factors for cardiovascular mortality and morbidity: the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S54–S64
24.
go back to reference Mattock MB, Barnes DJ, Viberti GC et al (1998) Microalbuminuria and coronary heart disease in NIDDM. An incidence study. Diabetes 47:1786–1792 Mattock MB, Barnes DJ, Viberti GC et al (1998) Microalbuminuria and coronary heart disease in NIDDM. An incidence study. Diabetes 47:1786–1792
25.
go back to reference Bruno G, Cavallo-Perin P, Bargero G et al (1996) Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of non-insulin-dependent diabetic subjects. Diabetes Care 19:43–47 Bruno G, Cavallo-Perin P, Bargero G et al (1996) Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of non-insulin-dependent diabetic subjects. Diabetes Care 19:43–47
26.
go back to reference Bruno G, Cavallo-Perin P, Bargero G et al (1999) Cardiovascular risk profile of type 2 diabetic patients cared for by general practitioners or by a diabetes clinic: a population-based study. J Clin Epidemiol 52:413–417 Bruno G, Cavallo-Perin P, Bargero G et al (1999) Cardiovascular risk profile of type 2 diabetic patients cared for by general practitioners or by a diabetes clinic: a population-based study. J Clin Epidemiol 52:413–417
27.
go back to reference Bruno G, LaPorte R, Merletti F, Biggeri A, McCarty D, Pagano G (1994) National diabetes programmes: application of capture–recapture to “count” diabetes? Diabetes Care 17:548–556 Bruno G, LaPorte R, Merletti F, Biggeri A, McCarty D, Pagano G (1994) National diabetes programmes: application of capture–recapture to “count” diabetes? Diabetes Care 17:548–556
28.
go back to reference Bruno G, Biggeri A, Merletti F et al (2003) Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes. A 10-year prospective study. Diabetes Care 26:2353–2358 Bruno G, Biggeri A, Merletti F et al (2003) Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes. A 10-year prospective study. Diabetes Care 26:2353–2358
29.
go back to reference Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241 Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241
30.
go back to reference Ritz E (2003) Albuminuria and vascular damage. The vicious twins. N Engl J Med 348:2349–2352 Ritz E (2003) Albuminuria and vascular damage. The vicious twins. N Engl J Med 348:2349–2352
31.
go back to reference Hanley AJG, Festa A, D’Agostino RB et al (2004) Metabolic and inflammation variable clusters and prediction of type 2 diabetes. Factor analysis using directly measured insulin sensitivity. Diabetes 53:1773–1781 Hanley AJG, Festa A, D’Agostino RB et al (2004) Metabolic and inflammation variable clusters and prediction of type 2 diabetes. Factor analysis using directly measured insulin sensitivity. Diabetes 53:1773–1781
32.
go back to reference Bruno G, Cavallo-Perin P, Bargero G et al (2001) Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes Metab Res Rev 17:124–130 Bruno G, Cavallo-Perin P, Bargero G et al (2001) Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes Metab Res Rev 17:124–130
33.
go back to reference Ceriello A (1997) Fibrinogen and diabetes mellitus: is it time for intervention trials? Diabetologia 40:731–734 Ceriello A (1997) Fibrinogen and diabetes mellitus: is it time for intervention trials? Diabetologia 40:731–734
34.
go back to reference Kirk A, Mutrie N, MacIntyre P, Fisher M (2004) Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with type 2 diabetes. Diabetologia 47:821–832 Kirk A, Mutrie N, MacIntyre P, Fisher M (2004) Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with type 2 diabetes. Diabetologia 47:821–832
35.
go back to reference Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Attending the diabetes center is associated with reduced cardiovascular mortality in type 2 diabetic patients: the Verona Diabetes Study. Diabetes Metab Res Rev 15:170–174 Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Attending the diabetes center is associated with reduced cardiovascular mortality in type 2 diabetic patients: the Verona Diabetes Study. Diabetes Metab Res Rev 15:170–174
Metadata
Title
Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study
Authors
G. Bruno
F. Merletti
A. Biggeri
G. Bargero
S. Ferrero
G. Pagano
P. Cavallo-Perin
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1667-1

Other articles of this Issue 3/2005

Diabetologia 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.